Formidable Sarmat: Satan’s successor that can pierce any defenseMilitary & Defense October 25, 16:37
Russia seeks to grasp US intentions to respond to more possible sanctionsRussian Politics & Diplomacy October 25, 16:31
Isinbayeva calls for joint efforts to fight doping at global levelSport October 25, 16:11
Kremlin believes Putin knows about financial situation of RosneftegazBusiness & Economy October 25, 16:09
Russian lawmaker cites US hostile policy as reason for suspending plutonium dealRussian Politics & Diplomacy October 25, 15:33
Russian forces assume combat duty in all Arctic garrisons — ministryMilitary & Defense October 25, 15:13
Aviation Committee completes probe into Falcon jet crash in Moscow’s Vnukovo airportWorld October 25, 15:04
Turkey, Russia exchange intelligence information on Syria — ministerWorld October 25, 14:38
Kremlin comments on hacker allegations against Putin's aide SurkovRussian Politics & Diplomacy October 25, 14:17
VIENNA, Sept. 18, 2014 /PRNewswire/ -- Preliminary data presented today highlighted the psychosocial benefits – important to optimal quality of life – of the integrated Animas® Vibe™ insulin pump and continuous glucose monitoring (CGM) system among patients with type 1 diabetes. Treatment satisfaction after switching to Animas® Vibe™, regardless of being previously naive to insulin pump therapy or a current pump user, was high (on a scale from 0 to 100, the mean value was 72).
Using the Insulin Treatment Satisfaction Questionnaire (ITSQ)[i], the study compared perceptions of insulin therapies from patients who switched from using multiple daily injections or an insulin pump to Animas® Vibe™, a latest generation insulin pump equipped with CGM capabilities. The study found 95% of participants said they would recommend Animas® Vibe™ to others. Direct feedback from study participants included positive statements such as, "I am very happy with my insulin pump. I can accept my disease better and feel just like other people. I feel less stressed and anxious than before. I feel more controlled in terms of my blood sugars." In addition to overall treatment satisfaction, feedback was collected regarding specific Animas® Vibe™ features; 88.9% of patients surveyed were satisfied with ease of use, 95.5% were satisfied with giving a bolus at meal or snack time, and 74.4% were satisfied with warnings and alarm safety systems.
"Diabetes is more than just maintaining healthy blood glucose levels," said Dr. Brian Levy, Chief Medical Officer, Animas Corporation. "This study is important because it reveals the mental and emotional benefits that integrated continuous glucose monitoring (CGM) insulin pump therapy can provide for patients, factors that are equally vital to successful diabetes management."
Interim results from this observational study were shared at the European Association for the Study of Diabetes (EASD) 50th Annual Meeting in Vienna, Austria. The Animas® Vibe™ Insulin Pump is indicated for continuous subcutaneous insulin infusion for the management of insulin-requiring diabetes in adult and pediatric patients. It is intended to accept and display data from the glucose sensor. The system is also a glucose-monitoring device indicated for detecting trends and tracking patterns in persons age 2 and older with diabetes. Animas® Vibe™ is available in 18 countries worldwide, including Europe, Asia Pacific, and Canada.
CHOICE (Comparing perception of insulin therapies for T1D patients with the aim to improve quality of care) is a multicentre, multinational, prospective observational study designed to address the knowledge deficit regarding how people with T1D respond to changes in their insulin delivery methods, particularly when switching to the Animas® Vibe™ a latest generation insulin pump enabled with continuous glucose monitoring. People with T1D from five EU countries were included, comprising an insulin pump naive group and an insulin pump experienced group. Interim data are reported for 190 respondents (mean age: 39.7 years; mean disease duration: 19.6 years) from three countries: France, Ireland and the UK.
With a shared vision of "creating a world without limits" for people with diabetes, Animas is a part of Johnson & Johnson Diabetes Solutions Companies, a cross-company collaboration that reflects an ongoing commitment to better serve the diabetes community with integrated solutions that meet the needs of people with diabetes across the continuum of care. Animas provides a wide range of insulin delivery products for people living with diabetes, including the OneTouch® Ping® Glucose Management System, Animas® Vibe™ insulin pump and CGM system, and the Animas® 2020 insulin pump (Note: Not all products are available in all countries). Animas, from the Latin word meaning "true inner self or soul," has been committed since 1996 to meeting individual patient needs through the development of life-performance technology and customer service 24 hours a day, 7 days a week, 365 days a year. To learn more about Animas, visit www.animas.com.
[i] Insulin Treatment Satisfaction Questionnaire (ITSQ) is a psychometrically validated questionnaire available in different languages, developed to evaluate the treatment satisfaction with a range of insulin therapies, and provides a basis upon which new data can be compared.